Annexon Stock Fair Value Calculation – “ANNEXON’s Geographic Atrophy Candidate Fails in Phase 2 Trial, Stock Price Drops 20%”.

May 25, 2023

Trending News 🌧️

ANNEXON ($NASDAQ:ANNX), a biopharmaceutical company focused on developing novel treatments for rare and difficult-to-treat diseases, recently suffered a major setback in its clinical trial for a geographic atrophy candidate. The Phase 2 trial failed to meet its primary endpoint, resulting in a 20% decline in its stock price. The failure of the Phase 2 trial is a major blow to ANNEXON and its shareholders.

The company’s stock had been rising steadily before the news broke, but it has since dropped significantly. It remains to be seen how ANNEXON will respond to this setback and whether it can recover and continue to develop treatments for rare and difficult-to-treat diseases.

Analysis – Annexon Stock Fair Value Calculation

At GoodWhale, we have conducted a thorough analysis of ANNEXON‘s fundamentals. After our calculations, we believe that the fair value of ANNEXON’s stock is $8.0. This was determined using our proprietary Valuation Line. At the moment, ANNEXON’s stock is being traded at $5.2, which values it at 34.9% lower than its fair value. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis
  • About the Company

  • ANNEXONs_Geographic_Atrophy_Candidate_Fails_in_Phase_2_Trial_Stock_Price_Drops_20.”>Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Annexon. More…

    Total Revenues Net Income Net Margin
    0 -145.25
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Annexon. More…

    Operations Investing Financing
    -119.01 9.71 140.47
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Annexon. More…

    Total Assets Total Liabilities Book Value Per Share
    268.78 53.92 4.05
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Annexon are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    FCF Margin ROE ROA
    -42.4% -35.2%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items

  • Peers

    The company’s lead product candidate, ANX005, is a monoclonal antibody that targets the C1q protein. The company is also developing ANX007, a monoclonal antibody that targets the C3 protein, for the treatment of autoimmune and inflammatory diseases.

    – Larimar Therapeutics Inc ($NASDAQ:LRMR)

    Larimar Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing new treatments for autoimmune and inflammatory diseases. The company has a market capitalization of 128.08 million as of 2022 and a return on equity of -73.95%. The company’s products are in various stages of development and have not yet been approved by the US Food and Drug Administration.

    – DICE Therapeutics Inc ($NASDAQ:DICE)

    DICE Therapeutics is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of novel therapeutics for the treatment of cancer. The company’s lead product candidate is DICE-945, a first-in-class, small molecule inhibitor of the PI3K/mTOR pathway. DICE-945 is currently being evaluated in a Phase I clinical trial in patients with advanced solid tumors.

    – IO Biotech Inc ($NASDAQ:IOBT)

    Asterias Biotherapeutics Inc is a biotechnology company. The Company is engaged in the development of regenerative medicine therapies based on pluripotent stem cells. The Company’s product candidates include AST-OPC1 (oligodendrocyte progenitor cells), AST-VAC2 (antigen-presenting autologous dendritic cells), and AST-VAC3 (folate receptor alpha-targeted dendritic cells).


    Annexon, Inc. is an immunobiology company that develops therapies for neurodegenerative diseases. Recently, the company announced that a Phase 2 clinical trial for one of its geographic atrophy (GA) candidates failed to meet its primary endpoints. This news caused the stock price to drop by 20%, making it an unfavorable investment opportunity.

    However, Annexon still has several other GA candidates in development, as well as a number of other potential therapies in its pipeline. Investors should conduct further research and pay attention to future developments before investing in the company. It’s also important to note that Annexon is not yet profitable, and there is no guarantee that its therapies will prove successful in the future.

    Recent Posts

    Leave a Comment